NTL Healthcare announced on the 20th that they showed the CerviCARE^® AI, which is an artificial intelligence (AI) cervical cancer screening system,

at the 28th Asia and Oceania Federation of Obstetrics and Gynecology Congress (AOFOG 2024 Congress) on 18th to 20th May 2024 at BEXCO, Busan,

under the theme "Quantum Leap for Women’s Health in Asia Oceania.”

 

Having 80% of the domestic market share for cervical cancer screening in obstetrics and gynecology, NTL Healthcare also presented a feminine cleanser

containing Human Blood Derived Natural Killer Cell Conditioned Media Extract, 'iner:y NK^®,' at this congress. Through the exhibition,

they met with buyers and hospital officials from major Asian countries such as India, Pakistan, China, Japan, Singapore, the Philippines, Indonesia,

as well as 20 other countries including the UK, France, and Saudi Arabia.

 

Taehee Kim, CEO of NTL Healthcare, stated, " CerviCARE^® AI is a system that allows all women, regardless of borders and regions,

to safely and conveniently undergo cervical cancer screening" and mentioned, "In addition to CerviCARE^® AI, various platforms focusing on

obstetrics and gynecology and women's diseases will be introduced."

 

NTL Healthcare is an AI femtech company that provides various women's health services. They have developed the CerviCARE^® AI and are expanding them globally.